Cellular delivery of cationic lipid nanoparticle-based SMAD3 antisense oligonucleotides for the inhibition of collagen production in keloid fibroblasts

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 82, Issue 1, 2012, Pages 19-26

  Jin, Su Eon ^a   Kim, Chong Kook ^a,b   Kim, Yang Bae ^a  

^a Seoul National University   (South Korea)

^b Inje University   (South Korea)

Author keywords

Antisense oligonucleotides; Cationic lipid nanoparticles; Cellular delivery; Fibrosis; Keloid fibroblasts; SMAD3

Indexed keywords

3 [N (N',N' DIMETHYLAMINOETHANE)CARBAMOL]CHOLESTEROL; ANTISENSE OLIGONUCLEOTIDE; CATIONIC LIPID NANOPARTICLE; COLLAGEN TYPE 1; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; LIPID; POLYSORBATE 20; SMAD3 PROTEIN; SOLID LIPID NANOPARTICLE; TRIMYRISTIN; UNCLASSIFIED DRUG;

ARTICLE; ATOMIC FORCE MICROSCOPY; DRUG DELIVERY SYSTEM; KELOID; LIGHT SCATTERING; MOLECULAR SIZE; PROTEIN EXPRESSION; SKIN FIBROBLAST;

CELLS, CULTURED; COLLAGEN TYPE I; DRUG STABILITY; DRUG STORAGE; FIBROBLASTS; FIBROSIS; HUMANS; KELOID; LIGHT; LIPIDS; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; PARTICLE SIZE; SCATTERING, RADIATION; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84866045340     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.05.015     Document Type: Article

References (30)

1. O. Seifert, and U. Mrowietz Keloid scarring: bench and bedside Arch. Dermatol. Res. 301 2009 259 272
2. A. Al-Attar, S. Mess, J.M. Thomassen, C.L. Kauffman, and S.P. Davison Keloid pathogenesis and treatment Plast. Reconstr. Surg. 117 2006 286 300
3. O. Bock, G. Schmid-Ott, P. Malewski, and U. Mrowietz Quality of life of patients with keloid and hypertrophic scarring Arch. Dermatol. Res. 297 2006 433 438
4. D.G. Greenhalgh The role of apoptosis in wound healing Int. J. Biochem. Cell Biol. 30 1998 1019 1030
5. K.C. Flanders Smad3 as a mediator of the fibrotic response Int. J. Exp. Pathol. 85 2004 47 64
6. P. Bonniaud, P.J. Margetts, K. Ask, K. Flanders, J. Gauldie, and M. Kolb TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis J. Immunol. 175 2005 5390 5395
7. J. Zhao, W. Shi, Y.L. Wang, H. Chen, P. Bringas Jr., M.B. Datto, J.P. Frederick, X.F. Wang, and D. Warburton Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice Am. J. Physiol. Lung Cell Mol. Physiol. 282 2002 L585 593
8. G.S. Chin, W. Liu, Z. Peled, T.Y. Lee, D.S. Steinbrech, M. Hsu, and M.T. Longaker Differential expression of transforming growth factor-β receptors I and II and activation of Smad 3 in keloid fibroblasts Plast. Reconstr. Surg. 108 2001 423 429
9. C.A. Stein, and Y.C. Cheng Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261 1993 1004 1012
10. S.T. Crooke Progress in antisense technology Annu. Rev. Med. 55 2004 61 95
11. J. Temsamani, G.S. Pari, and P. Guinot Antisense approach for the treatment of cytomegalovirus infection Expert. Opin. Investig. Drugs 6 1997 1157 1167
12. I.S. Zuhorn, J.B. Engberts, and D. Hoekstra Gene delivery by cationic lipid vectors: overcoming cellular barriers Eur. Biophys. J. 36 2007 349 362
13. M. Junghans, S.M. Loitsch, S.C. Steiniger, J. Kreuter, and A. Zimmer Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides Eur. J. Pharm. Biopharm. 60 2005 287 294
14. C. Tros de Ilarduya, Y. Sun, and N. Düzgüneş Gene delivery by lipoplexes and polyplexes Eur. J. Pharm. Biopharm. 40 2010 159 170
15. R.H. Muller, K. Mader, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
16. C. Olbrich, U. Bakowsky, C.-M. Lehr, R.H. Müller, and C. Kneuer Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA J. Control. Release 77 2001 345 355
17. N. Pedersen, S. Hansen, A.V. Heydenreich, H.G. Kristensen, and H.S. Poulsen Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands Eur. J. Pharm. Biopharm. 62 2006 155 162
18. A. del Pozo-Rodríguez, D. Delgado, M.A. Solinís, A.R. Gascón, and J.L. Pedraz Solid lipid nanoparticles: formulation factors affecting cell transfection capacity Int. J. Pharm. 339 2007 261 268
19. S.H. Choi, S.-E. Jin, M.-K. Lee, S.-J. Lim, J.-S. Park, B.-G. Kim, W.S. Ahn, and C.-K. Kim Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells Eur. J. Pharm. Biopharm. 68 2008 545 554
20. M.-K. Lee, S.-J. Lim, and C.-K. Kim Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles Biomaterials 28 2007 2137 2146
21. Y. Zhang, H. Li, J. Sun, J. Gao, W. Liu, B. Li, Y. Guo, and J. Chen DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery Int. J. Pharm. 390 2010 198 207
22. M.D. Kearns, Y.N. Patel, and M. Savva Physicochemical characteristics associated with transfection of cationic cholesterol-based gene delivery vectors in the presence of DOPE Chem. Phys. Lipids 163 2010 755 764
23. B. Siekmann, and K. Westesen Submicron-sized parenteral carrier systems based on solid lipids Pharm. Pharmacol. Lett. 1 1992 123 126
24. S. Doktorovova, R. Shegokar, E. Rakovsky, E. Gonzalez-Mira, C.M. Lopes, A.M. Silva, P. Martins-Lopes, R.H. Muller, and E.B. Souto Cationic solid lipid nanoparticles (cSLN): structure, stability and DNA binding capacity correlation studies Int. J. Pharm. 420 2011 341 349
25. J. Sitterberg, A. Özcetin, C. Ehrhardt, and U. Bakowsky Utilising atomic force microscopy for the characterisation of nanoscale drug delivery systems Eur. J. Pharm. Biopharm. 74 2010 2 13
26. A. del Pozo-Rodríguez, D. Delgado, M.A. Solinís, A.R. Gascón, and J.L. Pedraz Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells Int. J. Pharm. 360 2008 177 183
27. R.L. Juliano, X. Ming, and O. Nakagawa Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides Bioconjug. Chem. 23 2 2011 147 157
28. T.T. Phan, I.J. Lim, O. Aalami, F. Lorget, A. Khoo, E.K. Tan, A. Mukhopadhyay, and M.T. Longaker Smad3 signalling plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions J. Pathol. 207 2005 232 242
29. Z. Wang, Z. Gao, Y. Shi, Y. Sun, Z. Lin, H. Jiang, T. Hou, Q. Wang, X. Yuan, X. Zhu, H. Wu, and Y. Jin Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts J. Plast. Reconstr. Aesthet. Surg. 60 2007 1193 1199
30. G. Latella, A. Vetuschi, R. Sferra, V. Catitti, A. D'Angelo, and G. Zanninelli Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice Liver Int. 29 7 2009 997 1009